| M A TE RI A L S A ND M E TH ODS
This study was designed as a prospective clinical trial. Nine cats, owned by University of Wisconsin School of Veterinary Medicine or Veterinary Care Hospital staff or students, were enrolled in the study. Cats were considered healthy if their physical and neurologic examinations did not identify any clinically relevant abnormalities and their packed cell volume, total protein concentration and serum biochemical analysis (sodium, potassium, chloride, total CO 2 , anion gap, glucose, urea nitrogen, creatinine, total protein, albumin, globulin, alanine amino transferase, and alkaline phosphatase) results were within the normal reference range. Informed consent was obtained from all owners. The study was approved by the University of Wisconsin's Institutional Animal Care and Use Committee. Enrollment criteria included: (1) no history of epileptic seizures or other neurologic disease, (2) no concurrent medications other than heartworm or flea control products, (3) no concurrent participation in ongoing clinical studies or participation within the preceding 30 days, and (4) a minimum body weight of 5 kg. A single 500 mg XRL tablet (Solco Healthcare US, Cranbury, New Jersey) was administered PO with food q24h at home by owners for 10 days. All owners were requested to keep a daily log on a provided record form, including the time of XRL tablet administration, if consumption of food occurred with tablet administration, and observed adverse effects during the study period. Owners were informed of the adverse effects noted after single dose XRL administration healthy cats, but were instructed to record all adverse events, regardless if they had been reported previously.
On day 11 before to administration of the morning dose of medication, cats were hospitalized, and a blood sample (3.0 mL) was taken from a peripheral vein (medial saphenous or jugular vein). This sample was used for the trough (time 0) serum levetiracetam concentration and repeated serum biochemistry analysis. Packed cell volume was not repeated on day 11. The XRL tablet was administered by study personnel, and cats were provided immediate access to food. Subsequent blood samples (1.5 mL each) were collected by peripheral venipuncture (medial saphenous or jugular vein) into sterile tubes at 4, 6, and 8 hours after tablet administration for serum levetiracetam concentration assay.
A neurologic examination also was repeated on day 11. Cats were released to their owners and returned home after the final blood sample. Owners were instructed to administer one 500 mg XRL tablet on day 13 and 15 as a weaning protocol to minimize the risk of withdrawal epileptic seizures.
| Measurement of serum levetiracetam concentration
After clotting at room temperature, blood samples were centrifuged for 10 minutes at 1100g within 2 hours of collection. Serum samples were shipped to the Auburn Clinical Pharmacology Laboratory overnight, not on ice, for sample analysis. Upon receipt by the laboratory, serum was harvested and frozen at 2208C until analysis.
At the time of sample analysis, samples were thawed at room temperature and then vortexed to assure homogeneity. Levetiracetam was detected and quantitated in feline serum using a Food and Drug Administration immunoassay approved for humans on a general chemistry analyzer, which is described elsewhere. 5, 9 The system was validated in feline serum using pooled feline serum to which had been added known concentrations of levetiracetam. During the validation process all control samples prepared with feline serum, produced results within 10% of the target serum concentration. Subsequent analysis was based on the manufacturer's levetiracetam calibrator and control kits. The upper and lower limits of quantitation were 100 and 2 lg/mL, respectively. 9 The coefficients of variation (CV[%]) for the low, medium and high controls of 7.5, 30, and 75 mg/mL in feline serum were 4.7%, 3%, and 3%, respectively.
Descriptive statistics were determined using commercially available software (Microsoft Excel, 2013). Data were reported for each time point using median and range serum levetiracetam concentrations.
The time to maximal concentration (T max ) and maximal concentration (C max ) reported were based on sampling times in our study and may not represent true T max or C max . Successful outcome was defined as trough serum levetiracetam concentrations 5 lg/mL and minimal to no adverse effects at peak serum concentrations. No therapeutic reference interval has been established for cats and therefore the therapeutic reference interval in humans (5-45 lg/mL) was used for reference.
| RE S U L TS
All 9 cats completed the study. All doses were administered in the morning at home. No administration difficulty was reported by owners during the 10-day period. Two cats had medication placed in commercial canned food and were able to consume the pill without crushing it.
All remaining cats swallowed the tablets whole after direct administration to the oropharynx. All cats were reported to have eaten food with, or shortly after XRL administration on days 1-10. Physical and neurologic examinations were normal for all cats at enrollment and on day 
| D I SCUSSION
Our results indicate that median serum levetiracetam concentrations at day 11 were above the minimum therapeutic range used in humans (5 lg/mL) at all time points and the drug was well tolerated throughout the treatment period. Three sampling times (4, 6, and 8 hours) were used to estimate peak serum concentration based on the previously determined mean (SD) T max of 4.9 (1.6) hours after single dose XRL administration in healthy cats. 8 However, peak serum concentrations were not achieved in 2 cats by 8 hours, suggesting a wide inter-animal variation of T max . Mean (SD) serum levetiracetam concentrations at trough were 8.0 (4.15) lg/mL, indicating minimal drug accumulation.
Therapeutic drug monitoring of serum levetiracetam concentrations at trough should be considered to establish a therapeutic range for a given individual, especially if therapeutic success is not achieved or an increase in adverse events is noted.
The lack of clinically relevant serum biochemical changes in our study is consistent with previous observations after multiple dose IRL administration in cats. 6 Minimal drug accumulation was expected based on the half-life and dosing interval, but our study was conducted over 11 days to allow for a longer assessment of adverse clinical effects. Serious adverse effects of levetiracetam in cats appear to be uncommon, but mild transient ptyalism, inappetence, mild lethargy, ataxia, and polydipsia have been reported after IRL administration, [4] [5] [6] and sedation and diarrhea were reported after a single dosage of XRL. 8 Although a higher incidence of adverse effects may be expected at high serum concentrations, no correlation between serum concentration and adverse events was found in a previous study of human pediatric epileptic patients. 10 Our findings appear to be in agreement with these findings in children.
A therapeutic range for levetiracetam has been extrapolated from data in humans because a therapeutic range currently is unavailable for cats. 5, 6 Therapeutic range reflects the range of serum concentrations of a specific drug in which a therapeutic response can be expected in a given patient population. 11 If serum drug concentrations exceed the upper limit of the therapeutic range, the risk of adverse events may increase. The mean C max of levetiracetam was above the human therapeutic range in our study. Therefore, despite the lack of adverse effects observed in our study, veterinarians are advised to monitor for adverse effects in cats receiving chronic administration of 500 mg XRL. Few, mild reported adverse effects in our study suggest XRL was well tolerated despite the high C max . Notably, our study was not designed as a multiple dose toxicity study, and therefore the short observation period may underestimate the true incidence of adverse effects. Prescribing clinicians should be aware of potential adverse effects because of the high C max , and consider alternative AED if adverse effects are intolerable in an individual cat.
Despite the large tablet size, all 9 cats received the medication successfully without reported difficulty. However, all owners were veterinary students, staff, or faculty and therefore it remains unknown if laypersons treating more fractious cats would encounter greater 
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